IGF2BP3 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population derived from the human lung adenocarcinoma cell line NCI-H1975, featuring targeted disruption of the IGF2BP3 gene. This heterogeneous pool provides a robust loss-of-function model for examining the post-transcriptional regulatory functions of IGF2BP3 in a relevant non-small cell lung cancer (NSCLC) background. As a polyclonal product, it captures diverse editing outcomes, enabling population-level analyses without single-cell cloning artifacts.
The NCI-H1975 host line originates from a non-smoking female patient with lung adenocarcinoma and harbors somatic EGFR L858R and T790M mutations. These alterations drive constitutive EGFR signaling and confer resistance to first- and second-generation tyrosine kinase inhibitors, making the line a critical tool for investigating acquired therapy resistance mechanisms. The cells exhibit epithelial morphology and are widely employed in oncogenic pathway studies, drug sensitivity profiling, and metastasis research.
IGF2BP3 encodes an oncofetal RNA-binding protein that stabilizes and modulates translation of target mRNAs, including CD44, MYC, CCND1, and BCL2, thereby influencing cell proliferation, apoptosis, and motility. Its expression is transcriptionally upregulated by MYC and LIN28B and post-transcriptionally repressed by let-7 miRNA. IGF2BP3 interacts with paralogs IGF2BP1 and IGF2BP2, the RNA-binding protein ELAVL1/HuR, and stress granule constituents, forming ribonucleoprotein complexes that integrate signals from TGF-??/SMAD, PI3K/AKT, and MAPK/ERK cascades. In NCI-H1975 cells, IGF2BP3-dependent regulation of these targets reinforces oncogenic pathways downstream of mutant EGFR, sustaining growth and survival.
In the context of NCI-H1975 cells driven by EGFR L858R/T790M, IGF2BP3 ablation is predicted to attenuate key signaling nodes by diminishing the stability of MYC and CD44 transcripts, thereby reducing downstream PI3K/AKT and MAPK/ERK activity. This may counteract the hyperproliferative phenotype and restore sensitivity to third-generation EGFR inhibitors like osimertinib. Furthermore, loss of IGF2BP3 likely impairs epithelial-mesenchymal transition programs and invasive behavior, making this knockout pool ideal for elucidating the crosstalk between RNA metabolism and kinase inhibitor resistance in NSCLC.
Research applications include functional dissection of IGF2BP3??s role in mRNA regulation via RNA immunoprecipitation and transcriptomic profiling, assessment of drug response using EGFR-targeted agents, and phenotypic assays such as MTT, wound healing, and transwell invasion. This polyclonal knockout model supports population-level studies of gene disruption effects on cell signaling, tumorigenicity, and metastatic potential. It is also suitable for CRISPR screens, validation of RNA-based therapeutics, and combinatorial treatment studies. For additional information, please contact Ascent Research.
